↓ Skip to main content

Non-covalent interactions involving halogenated derivatives of capecitabine and thymidylate synthase: a computational approach

Overview of attention for article published in SpringerPlus, February 2016
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
54 Mendeley
Title
Non-covalent interactions involving halogenated derivatives of capecitabine and thymidylate synthase: a computational approach
Published in
SpringerPlus, February 2016
DOI 10.1186/s40064-016-1844-y
Pubmed ID
Authors

Adhip Rahman, Mohammad Mazharol Hoque, Mohammad A. K. Khan, Mohammed G. Sarwar, Mohammad A. Halim

Abstract

Capecitabine, a fluoropyrimidine prodrug, has been a frequently chosen ligand for the last one and half decades to inhibit thymidylate synthase (TYMS) for treatment of colorectal cancer. TYMS is a key enzyme for de novo synthesis of deoxythymidine monophosphate and subsequent synthesis of DNA. Recent years have also seen the trait of modifying ligands using halogens and trifluoromethyl (-CF3) group to ensure enhanced drug performance. In this study, in silico modification of capecitabine with Cl, Br, I atoms and -CF3 group has been performed. Density functional theory has been employed to optimize the drug molecules and elucidate their thermodynamic and electrical properties such as Gibbs free energy, enthalpy, electronic energy, dipole moment and frontier orbital features (HOMO-LUMO gap, hardness and softness). Flexible and rigid molecular docking have been implemented between drugs and the receptor TYMS. Both inter- and intra-molecular non-covalent interactions involving the amino acid residues of TYMS and the drug molecules are explored in details. The drugs were superimposed on the resolved crystal structure (at 1.9 Å) of ZD1694/dUMP/TYMS system to shed light on similarity of the binding of capecitabine, and its modifiers, to that of ZD1694. Together, these results may provide more insights prior to synthesizing halogen-directed derivatives of capecitabine for anticancer treatment.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 22%
Researcher 7 13%
Student > Bachelor 7 13%
Student > Ph. D. Student 5 9%
Student > Doctoral Student 2 4%
Other 7 13%
Unknown 14 26%
Readers by discipline Count As %
Chemistry 15 28%
Pharmacology, Toxicology and Pharmaceutical Science 7 13%
Biochemistry, Genetics and Molecular Biology 4 7%
Agricultural and Biological Sciences 3 6%
Medicine and Dentistry 3 6%
Other 8 15%
Unknown 14 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2016.
All research outputs
#20,313,158
of 22,854,458 outputs
Outputs from SpringerPlus
#1,459
of 1,849 outputs
Outputs of similar age
#252,335
of 298,866 outputs
Outputs of similar age from SpringerPlus
#122
of 153 outputs
Altmetric has tracked 22,854,458 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,849 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,866 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.